Hemab Therapeutics Pulls Back After 53% IPO Surge
Hemab Therapeutics Holdings is set to open Wednesday pre-market at $27.47, up around 53% from its $18 IPO price. Investors now turn to the company’s management, who are scheduled to present at the Jefferies Global Healthcare Conference on Thursday. Shares finished Tuesday up 1.25% after a volatile first month since going public, according to market data. Hemab is still a new Nasdaq biotech, so the focus has shifted away from the listing to whether it can keep its lead drug program on track for late-stage trials. The company is slated for a fireside chat at 9:20 a.m. ET on June 4 in New York at a healthcare conference that runs from June 2-4.